Protocol Ledger

NCT04303780 · Phase III · COMPLETED

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Interventional Phase III clinical trial protocol NCT04303780 sponsored by Amgen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-04 Enrollment: 345 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04303780
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)345 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04303780
Protocol FieldVerified Registry Value
NCT IdentifierNCT04303780
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment345 participants (ACTUAL)
Registered Start Date2020-06-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI